JAK inhibitor articles covering treatments such as upadacitinib and tofacitinib, including safety, approvals, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...
